Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
Go back to Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 42.00 -0.92 (2.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.92 | 52 Week High | $26.84 | |||
| Open | $42.89 | 52 Week Low | $9.51 | |||
| Day High | $42.89 | P/E | N/A | |||
| Day Low | $41.60 | EPS | $-2.62 | |||
| Volume | 1,182,919 | |||||
